Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart Combined With Anlotinib in Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in alveolar soft part sarcoma (ASPS), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2026; status: recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT07548177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548177.